000865195 001__ 865195
000865195 005__ 20210130002938.0
000865195 0247_ $$2doi$$a10.2967/jnumed.119.234757
000865195 0247_ $$2ISSN$$a0022-3123
000865195 0247_ $$2ISSN$$a0097-9058
000865195 0247_ $$2ISSN$$a0161-5505
000865195 0247_ $$2ISSN$$a1535-5667
000865195 0247_ $$2ISSN$$a2159-662X
000865195 0247_ $$2Handle$$a2128/24639
000865195 0247_ $$2pmid$$apmid:31519802
000865195 0247_ $$2WOS$$aWOS:000530831100030
000865195 037__ $$aFZJ-2019-04731
000865195 082__ $$a610
000865195 1001_ $$00000-0001-7329-6007$$aMaurer, Gabriele D$$b0
000865195 245__ $$a18 F-FET PET imaging in differentiating glioma progression from treatment-related changes – a single-center experience
000865195 260__ $$aNew York, NY$$bSoc.$$c2020
000865195 3367_ $$2DRIVER$$aarticle
000865195 3367_ $$2DataCite$$aOutput Types/Journal article
000865195 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1585832734_10314
000865195 3367_ $$2BibTeX$$aARTICLE
000865195 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000865195 3367_ $$00$$2EndNote$$aJournal Article
000865195 520__ $$aIn glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TRCs) remains challenging. Difficulties in classifying imaging alterations may result in a delay or an unnecessary discontinuation of treatment. PET using O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) has been shown to be a useful tool for detecting TP and TRCs. Methods: We retrospectively evaluated 127 consecutive patients with World Health Organization grade II–IV glioma who underwent 18F-FET PET imaging to distinguish between TP and TRCs. 18F-FET PET findings were verified by neuropathology (40 patients) or clinicoradiologic follow-up (87 patients). Maximum tumor-to-brain ratios (TBRmax) of 18F-FET uptake and the slope of the time–activity curves (20–50 min after injection) were determined. The diagnostic accuracy of 18F-FET PET parameters was evaluated by receiver-operating-characteristic analysis and χ2 testing. The prognostic value of 18F-FET PET was estimated using the Kaplan–Meier method. Results: TP was diagnosed in 94 patients (74%) and TRCs in 33 (26%). For differentiating TP from TRCs, receiver-operating-characteristic analysis yielded an optimal 18F-FET TBRmax cutoff of 1.95 (sensitivity, 70%; specificity, 71%; accuracy, 70%; area under the curve, 0.75 ± 0.05). The highest accuracy was achieved by a combination of TBRmax and slope (sensitivity, 86%; specificity, 67%; accuracy, 81%). However, accuracy was poorer when tumors harbored isocitrate dehydrogenase (IDH) mutations (91% in IDH-wild-type tumors, 67% in IDH-mutant tumors, P < 0.001). 18F-FET PET results correlated with overall survival (P < 0.001). Conclusion: In our neurooncology department, the diagnostic performance of 18F-FET PET was convincing but slightly inferior to that of previous reports. 
000865195 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000865195 588__ $$aDataset connected to CrossRef
000865195 7001_ $$0P:(DE-HGF)0$$aBrucker, Daniel P$$b1
000865195 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b2
000865195 7001_ $$0P:(DE-HGF)0$$aFilipski, Katharina$$b3
000865195 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian P$$b4
000865195 7001_ $$0P:(DE-Juel1)132318$$aMottaghy, Felix M.$$b5$$ufzj
000865195 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b6
000865195 7001_ $$0P:(DE-HGF)0$$aSteinbach, Joachim P$$b7
000865195 7001_ $$0P:(DE-HGF)0$$aHattingen, Elke$$b8
000865195 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b9$$eCorresponding author
000865195 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.119.234757$$gp. jnumed.119.234757 -$$n4$$p505-511$$tJournal of nuclear medicine$$v61$$x2159-662X$$y2020
000865195 8564_ $$uhttps://juser.fz-juelich.de/record/865195/files/Maurer_2019_Post%20Print_J%20Nucl%20Med_18F-FET%20PET%20imaging%20in%20differentiating%20glioma%20progression%20from%20treatment-related%20changes.pdf$$yPublished on 2019-09-13. Available in OpenAccess from 2020-03-13.
000865195 8564_ $$uhttps://juser.fz-juelich.de/record/865195/files/Maurer_2019_Post%20Print_J%20Nucl%20Med_18F-FET%20PET%20imaging%20in%20differentiating%20glioma%20progression%20from%20treatment-related%20changes.pdf?subformat=pdfa$$xpdfa$$yPublished on 2019-09-13. Available in OpenAccess from 2020-03-13.
000865195 909CO $$ooai:juser.fz-juelich.de:865195$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000865195 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b2$$kFZJ
000865195 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich$$b4$$kFZJ
000865195 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132318$$aForschungszentrum Jülich$$b5$$kFZJ
000865195 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b6$$kFZJ
000865195 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b9$$kFZJ
000865195 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000865195 9141_ $$y2020
000865195 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000865195 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000865195 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000865195 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2017
000865195 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000865195 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000865195 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000865195 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000865195 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2017
000865195 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000865195 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000865195 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000865195 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000865195 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000865195 920__ $$lyes
000865195 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000865195 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000865195 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x2
000865195 980__ $$ajournal
000865195 980__ $$aVDB
000865195 980__ $$aUNRESTRICTED
000865195 980__ $$aI:(DE-Juel1)INM-3-20090406
000865195 980__ $$aI:(DE-Juel1)INM-4-20090406
000865195 980__ $$aI:(DE-Juel1)INM-11-20170113
000865195 9801_ $$aFullTexts